Management of Aggressive PitNETs: Evidence Gaps, Molecular Clues, and a Roadmap for Clinical Trials

Area of Science:

• Endocrinology and Oncology
• Molecular Pathology

Background:

• Aggressive pituitary neuroendocrine tumors (Pit-NETs) are rare but highly morbid due to rapid growth and treatment resistance.
• Current prognostic and therapeutic strategies are lacking for these distinct lesions.

Purpose of the Study:

• To delineate the molecular underpinnings of aggressive Pit-NETs.
• To identify potential therapeutic targets and prognostic biomarkers.

Main Methods:

• Analysis of somatic variants (ATRX, TP53, SF3B1), chromosomal instability, and epigenetic remodeling.
• Single-cell and immune profiling to characterize tumor subpopulations.
• Review of clinical data on therapeutic responses.

Main Results:

• Recurrent genetic alterations and epigenetic profiles distinguish aggressive Pit-NETs.
• Proliferative, migratory, and immunoevasive cell subpopulations identified.
• Temozolomide shows consistent benefit; other therapies show emerging efficacy.

Conclusions:

• Aggressiveness in Pit-NETs is a multidimensional process influenced by molecular and cellular factors.
• Integrating molecular and imaging biomarkers is crucial for precise diagnosis and management.
• Further research and clinical trials are needed to refine treatment strategies.